Dr Steven Hofman

Dr Steven Hofman

Graduated at Leiden University in 1971. Specialises in clinical psychiatry. He worked in private practice as a hospital psychiatrist from 1979 until 2000. Dr Hofman is currently working as a private practicioner in complementary medicine at Capelle a/d Ijssel NL and as a part-time psychiatrist (senior responsible specialist) in a mental-health institue (Together, Berkel & Delft, NL).

Two years of experience with GcMAF treatment and Nagalase testing of  patients ( March 2011-now).

Nearly ten years ago Yamamoto described an immunotherapy that uses an endogenous protein substance (GcMAF) to predominantly stimulate the innate immune system, which is semi synthetically produced from Gc globulin (vitamin D Binding Protein,DBP) and is monitored with alfa-N-acetylgalactosaminidase (Nagalase) activity by testing blood.

Since March 2011 a number of patients with cancer have been treated. They were treated with GcMAF and their Nagalase levels in plasma were repeatedly tested (ELN). The cases will be presented.

With GcMAF Vitamin D was supplied as well, because the patients had low levels of Vitamin D at the start of the study, and in some cases other treatment was also given (e.g. acupuncture).

The results are positive: patients' wellbeing improved and Nagalase levels decreased.

A graph of four selected patients, in which the axes represent duration and Nagalase activity. A comparison with the curves published by N. Yamamoto et al. (2008) shown and discussed.

Comparing our results to the ones found by Yamamoto et al., the effect on the Nagalase activity is considerably slower in our group (2-4 times).

Possible factors for this difference: GcMAF prepared from different Gc-globulins, cq from different sources. Different enzyme treatment or pharmaceutic handling.  Diagnostic differences in the patients, the suppletion of vitamin D, or an inverse placebo-effect and other reasons.

The UK-GcMAF is safe, and it may be considered using it experimentally with diseases for which no evidence-based therapies are easily available, especially if there is an increased level of nagalase (screening required). In the core-clinical psychiatry we could have some surprises, considering results with ASD (Bradstreet et al, 2013).